HC Wainwright set a $2.00 price target on Interpace Diagnostics Group (NASDAQ:IDXG) in a research note published on Friday, TipRanks reports. The firm currently has a buy rating on the business services provider’s stock.

Separately, Oppenheimer initiated coverage on Interpace Diagnostics Group in a report on Thursday, September 26th. They issued an outperform rating and a $3.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $3.00.

NASDAQ IDXG opened at $0.78 on Friday. Interpace Diagnostics Group has a one year low of $0.67 and a one year high of $1.55. The stock has a 50-day moving average of $0.78 and a 200 day moving average of $0.76. The company has a market capitalization of $30.75 million, a price-to-earnings ratio of -1.81 and a beta of 2.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.75.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings data on Tuesday, August 13th. The business services provider reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Interpace Diagnostics Group had a negative return on equity of 42.91% and a negative net margin of 65.86%. The business had revenue of $6.27 million during the quarter, compared to the consensus estimate of $6.70 million. On average, equities analysts predict that Interpace Diagnostics Group will post -0.35 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. boosted its position in Interpace Diagnostics Group by 98.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock worth $32,000 after purchasing an additional 22,150 shares during the last quarter. River & Mercantile Asset Management LLP purchased a new position in Interpace Diagnostics Group in the second quarter worth about $468,000. Finally, Stonepine Capital Management LLC boosted its position in Interpace Diagnostics Group by 22.3% in the second quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock worth $1,271,000 after purchasing an additional 319,154 shares during the last quarter. 19.03% of the stock is currently owned by institutional investors and hedge funds.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Read More: Cost of Capital Explained

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.